US5627206A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tricyclic inhibitor of matrix metalloproteinases
Assignee: Warner Lambert Co LLC
•
Filing: 1995-06-02
•
Granted: 1997-05-06
•
Expires: 2015-06-02
Abstract
Abstract A tricyclic compound is described as well as pharmaceutical compositions of same, which is useful as an inhibitor of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) for the treatment of multiple sclerosis or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.
Inventors
- 👤 Donald Hupe
- 👤 Linda Lea Johnson
- 👤 Qi-Zhuang Ye
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:40
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/91
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
38 words
A method of treating multiple sclerosis comprising administering to a host suffering therefrom a therapeutically effective amount of the compound of Formula I ##STR2## or corresponding isomers thereof; or a pharmaceutically acceptable salt thereof in unit dosage form.
Claim 2
Independent Claim
38 words
A method of treating multiple sclerosis comprising administering to a host suffering therefrom a therapeutically effective amount of the compound of Formula I ##STR2## or corresponding isomers thereof; or a pharmaceutically acceptable salt thereof in unit dosage form.
Claim 3
Independent Claim
46 words
A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a host suffering therefrom a therapeutically effective amount of the compound of Formula I ##STR3## or corresponding isomers thereof; or a pharmaceutically acceptable salt thereof in unit dosage form.
Claim 4
Independent Claim
46 words
A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a host suffering therefrom a therapeutically effective amount of the compound of Formula I ##STR3## or corresponding isomers thereof; or a pharmaceutically acceptable salt thereof in unit dosage form.
Claim 5
Dependent Claim
20 words
A pharmaceutical composition comprising the compound of Formula I: ##STR4## in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
Claim 6
Dependent Claim
20 words
A pharmaceutical composition comprising the compound of Formula I: ##STR4## in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
Claim 7
Dependent Claim
41 words
A pharmaceutical composition adapted for administration as an agent for treating inflammatory diseases dependent upon tissue invasion by leukocytes comprising a therapeutically effective amount of the compound according to claim 3 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
Claim 8
Dependent Claim
35 words
A pharmaceutical composition adapted for administration as an agent for treating multiple sclerosis comprising a therapeutically effective amount of the compound according to claim 3 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-05 | 2000-11-04 | 2001-05-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-05 | 2004-11-04 | 2005-05-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-05 | 2008-11-04 | 2009-05-06 | $7700.00 | Window Closed / Lapsed |